Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Leeds, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV

Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:15 UTC

2863

Studies in scope

industry-sponsored, all four open statuses

1385

Recruiting now

open to new participants

542

Lead sponsors

across recruiting studies

Top sites

London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425

Trials with a site in Leeds

Status

Study

Lead sponsor

Phase

Enrol

UK sites

Start

Not yet open

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

NCT07335562Systemic Sclerosis

DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

London, Leeds, Sheffield

2027-02-03

Not yet open

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

NCT07441408Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

2,380

Birmingham, Cambridge, Edinburgh, London, Peterborough, Cottingham, Leeds, Oxford

2026-12-16

Not yet open

A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol

NCT07744386Healthy Male Volunteers

DrugsCHF10196·Dabigatran Etexilate·Rosuvastatin

Chiesi Farmaceutici S.p.A.

Phase 1

Leeds

2026-10-27

Not yet open

A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants

NCT07683793Healthy Volunteers

DrugsCHF10196·Pantoprazole

Chiesi Farmaceutici S.p.A.

Phase 1

Leeds

2026-10-14

Not yet open

Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults and Adults With Asthma

NCT07851623Asthma, Healthy Volunteers

Chiesi Farmaceutici S.p.A.

Phase 1

120

Leeds, London, Manchester

2026-10-01

Not yet open

Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

NCT07808151Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer

DrugsPorustobart·Keytruda·Pembrolizumab

Solstice Oncology, Inc.

Phase 2

100

Aberdeen, Cardiff, Glasgow, Leeds, London

2026-09-30

Recruiting

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

NCT07540988Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

466

Birmingham, Exeter, Lancaster, Leeds, Leicester, London, Manchester, Oxford

2026-09-17

Recruiting

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200Essential Thrombocythemia

DrugINCA033989

Incyte Corporation

Phase 3

426

Cambridge, Edinburgh, Harrow, Leeds, London, Newcastle upon Tyne, Oxford, Penzance

2026-09-08

Recruiting

Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT07665515Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Epitopea Ltd

Phase 1

Cambridge, Edinburgh, Glasgow, Leeds, Leicester, London, Preston, Sutton

2026-09

Recruiting

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

1,072

Cambridge, Leeds, London, Newcastle upon Tyne, Sheffield

2026-08-31

Not yet open

Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

NCT07682129Duchenne Muscular Dystrophy (DMD)

DrugsENTR-601-44·ENTR-601-45

Entrada Therapeutics, Inc.

Phase 2

Leeds, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford

2026-08

Recruiting

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT07497087Systemic Sclerosis

Boehringer Ingelheim

Phase 3

448

Bristol, Leeds, London, Salford

2026-07-27

Recruiting

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

NCT07554339Non-small Cell Lung Cancer

DrugsCalderasib·Durvalumab

Merck Sharp & Dohme LLC

Phase 3

310

Leeds

2026-06-18

Recruiting

An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT07583563Acromegaly

Camurus AB

Observational

200

Leeds

2026-06-05

Recruiting

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

117

Leicester, Liverpool, Belfast, Glasgow, Newcastle upon Tyne, Leeds, Bristol

2026-06-01

Recruiting

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular

Eli Lilly and Company

Phase 1

215

Leeds, Oxford

2026-05-28

Recruiting

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 2

Birmingham, Cambridge, Glasgow, Leeds, London, Manchester, Newcastle, Sheffield

2026-05-20

Recruiting

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

NCT07509151Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV

DrugSurovatamig

AstraZeneca

Phase 3

420

Edinburgh, Hampshire, Leeds, London, Manchester, Nottingham, Oxford, Sutton

2026-05-05

Recruiting

Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia

NCT07605845Immune Thrombocytopenia

Gliknik Inc.

Phase 1

Leeds

2026-04-14

Recruiting

Controlling Hyperactive Immunity With Long-lived Lymphocytes

NCT07473154Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic Disease

Quell Therapeutics Limited

Phase 1/2

Birmingham, Leeds, London, Manchester, Newcastle, Oxford

2026-04-10

Recruiting

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

NCT07522073Solid Tumors

DrugINCB161734

Incyte Corporation

Phase 3

588

Dundee, Guildford, Headington, Leeds, London, Manchester, Northwood, Norwich

2026-04-09

Recruiting

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

NCT05936580Hemophilia A

DrugNuwiq

Octapharma

Phase 4

Leeds

2026-04

Recruiting

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

NCT07326709Huntington Disease

DrugVotoplam

Novartis Pharmaceuticals

Phase 3

770

Exeter, Aberdeen, Cambridge, Cardiff, Glasgow, Leeds, London, Oxford

2026-03-24

Recruiting

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

NCT07387367Adenovirus Infections

SymBio Pharmaceuticals

Phase 3

180

Birmingham, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield, Sutton

2026-03-17

Recruiting

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497Non-small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Durvalumab

Bristol-Myers Squibb

Phase 3

850

Manchester, Newcastle upon Tyne, Birmingham, Cambridge, Cardiff, Guildford, Leeds, Liverpool

2026-03-16

Recruiting

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic

DrugsIdelalisib·Pirtobrutinib

Eli Lilly and Company

Phase 4

150

Hull, Leeds, Newmarket

2026-03-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849CRC (Colorectal Cancer)

DrugsINCA33890·Folfox·Bevacizumab

Incyte Corporation

Phase 3

700

Bristol, Cardiff, Leeds, London, Maidstone, Manchester, Sutton

2026-03-05

Not yet open

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects With Reduced Ejection Fraction

NCT07403058Heart Failure With Reduced Ejection Fraction (HFrEF)

Axon Therapies, Inc.

Not applicable

Leeds, London

2026-03-01

Recruiting

A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

NCT07187401Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia

Regeneron Pharmaceuticals

Phase 1/2

Leeds, London

2026-02-11

Recruiting

Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty

NCT07214311Prosthetic-joint Infection

Peptilogics

Phase 2/3

240

Cambridge, Edinburgh, Norwich, Leeds

2026-02-03

Recruiting

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer

DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin

AstraZeneca

Phase 3

2,130

Cambridge, Dundee, Leeds, London, Manchester, Oxford

2026-02-03

Recruiting

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

NCT07277231Chronic Lymphocytic Leukemia

DrugsSonrotoclax·Venclyxto·Acalabrutinib·Venclexta

BeOne Medicines

Phase 3

500

Birmingham, Bournemouth, Leeds, London, Norwich

2026-01-22

Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

NCT07287982Spinal Muscular Atrophy (SMA)

DrugARGX-119

argenx

Phase 2

Cambridge, London, Oxford, Sheffield, Glasgow, Birmingham, Leeds

2025-12-19

Recruiting

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

NCT07276581Rheumatoid Arthritis

AstraZeneca

Phase 2

320

Glasgow, Leeds, Luton, Staffordshire

2025-12-15

Recruiting

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07214779Ovarian Cancer

DrugINCB123667

Incyte Corporation

Phase 3

466

Cambridge, Cardiff, Guildford, Leeds, Liverpool, London, Manchester Greater, Northampton

2025-12-09

Recruiting

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab

AstraZeneca

Phase 3

1,100

Birmingham, Glasgow, Greater London, Leeds, London, Manchester

2025-12-04

Recruiting

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT07218926Gastrointestinal Neoplasms

DrugsIDRX-42·Sunitinib

GlaxoSmithKline

Phase 3

450

Manchester, Edinburgh, Cambridge, Leeds, London, Sheffield

2025-12-03

Recruiting

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT06930625Acromegaly

Debiopharm International SA

Phase 3

119

Birmingham, Leeds

2025-11-26

By invitation

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT07256392Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

1,370

Leeds, Bristol, Cambridge, Glasgow, North Finchley

2025-11-25

Recruiting

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

111

Leicester, Liverpool, Belfast, Glasgow, Newcastle upon Tyne, Leeds, Bristol

2025-11-19

Recruiting

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

NCT07186842Advanced Solid Cancers

BioNTech SE

Phase 1/2

245

Leeds, London, Manchester, Newcastle upon Tyne, Sutton

2025-11-18

Recruiting

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

1,275

Brighton, Romford, Coventry, Glasgow, Leeds, London, Nottingham

2025-11-11

Recruiting

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

NCT07170917Hidradenitis Suppurativa

DrugBrivekimig

Sanofi

Phase 2

208

London, Leeds

2025-11-06

Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

NCT07173751Breast Neoplasms

DrugsEribulin·Pumitamig·Gemcitabine·Carboplatin

BioNTech SE

Phase 3

558

Brighton, Bristol, Cottingham, Edinburgh, Leeds, London, Oxford, Rhyl

2025-10-30

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis

DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan

Eli Lilly and Company

Phase 3

1,630

Bath, Leeds, London, Manchester, Torquay

2025-10-22

Active, closed

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

NCT07176390Arthritis, Rheumatoid

DrugsTulisokibart·Methotrexate

Merck Sharp & Dohme LLC

Phase 2

185

Harlow, Leeds, London

2025-10-08

Recruiting

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1

NCT07179640Hypophosphatasia (HPP)

Alesta Therapeutics

Phase 1/2

120

Leeds

2025-09-30

Recruiting

PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB

NCT06789406Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Overactive Bladder (OAB)

Axonics, Inc.

Not applicable

Bradford, Wakefield, Leeds, London

2025-09-18

Recruiting

A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

NCT07047144Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3

DrugsApitegromab·Nusinersen·Risdiplam

Scholar Rock, Inc.

Phase 2

Leeds

2025-09-15

Active, closed

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

413

Antrim, Bath, Birmingham, Leeds, London, Londonderry, Luton, Preston

2025-09-13

Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Cabozantinib

Arcus Biosciences, Inc.

Phase 3

720

Cambridge, Cottingham, Exeter, Glasgow, Leeds, London, Manchester, Newcastle upon Tyne

2025-09-08

Recruiting

A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

NCT07136467Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa

AbbVie

Observational

2,795

London, Oxford, Leeds, Wakefield, Belfast, Cardiff, Walsall, Wolverhampton

2025-09-02

Recruiting

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45

NCT07038824Duchenne Muscular Dystrophy (DMD)

DrugENTR-601-45

Entrada Therapeutics, Inc.

Phase 1/2

Leeds, Liverpool, London, Manchester, Oxford

2025-08-30

Recruiting

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

NCT07160244Healthy

DrugPrevnar 20

Pfizer

Phase 3

6,000

Bristol, London, Manchester, Truro, Southampton, Oxford, Shropshire, Leeds

2025-08-25

Recruiting

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

DrugsEmpasiprubart·IVIG

argenx

Phase 3

218

Salford, Leeds, London

2025-08-22

Recruiting

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

150

Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London

2025-08-14

Recruiting

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

NCT06449001Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis

DrugDanicopan

Alexion Pharmaceuticals, Inc.

Phase 3

Leeds, London

2025-08-11

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Cambridge, Dundee, London, Glasgow, Bath, Guildford, Leeds, Reading

2025-08-06

Recruiting

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

NCT06721013Immune Thrombocytopenia (ITP)

DrugPirtobrutinib

Eli Lilly and Company

Phase 1/2

Bristol, Leeds, Leicester, London

2025-07-30

Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634Breast Cancer

DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole

Celcuity Inc

Phase 3

1,180

Cambridge, Bathgate, Rickmansworth, Maidstone, Taunton, Cottingham, Glasgow, Leeds

2025-07-24

Recruiting

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

NCT07001280Hereditary Angioedemas

CSL Behring

Observational

200

Cambridge, London, Manchester, Cardiff, Frimley, Birmingham, Leeds

2025-07-21

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT06976203Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

586

Manchester, London, Edinburgh, Oxford, Birmingham, Leeds, Motherwell, Sheffield

2025-07-21

Recruiting

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

NCT07284121Lung Cancer, Hepatocellular Carcinoma

DrugsTecentriq·Atezolizumab

Hoffmann-La Roche

Observational

700

Birmingham, Guildford, Leeds, Middlesbrough, Norfolk

2025-07-15

Recruiting

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

NCT06988605Atopic Dermatitis

Galderma R&D

Observational

1,000

London, Southampton, Watford, Kings Lynn, Harrogate, Sheffield, Birmingham, Leeds

2025-07-14

Recruiting

ELEVATE-HFpEF Clinical Study

NCT06678841Heart Failure With Preserved Ejection Fraction (HFpEF)

Medtronic Cardiac Rhythm and Heart Failure

Not applicable

700

Leeds, London, Manchester

2025-07-09

Active, closed

Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options

NCT06794554Chronic Pulmonary Aspergillosis

Mundipharma Research Limited

Phase 2

Cambridge, Derby, Dundee, Edinburgh, Leeds, London, Manchester

2025-06-30

Recruiting

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

NCT07037862Duchenne Muscular Dystrophy (DMD)

DrugENTR-601-44

Entrada Therapeutics, Inc.

Phase 1/2

Leeds, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford

2025-06-30

By invitation

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637Hidradenitis Suppurativa

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

835

Leeds, Salford

2025-06-27

Recruiting

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281Relapsing Multiple Sclerosis

DrugsRemibrutinib·Ocrelizumab

Novartis Pharmaceuticals

Phase 3

400

Sheffield, Leeds, London, Swansea

2025-06-23

Active, closed

A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

NCT06736990Idiopathic Pulmonary Fibrosis

Calluna Pharma AS

Phase 2

150

Birmingham, Edinburgh, Leeds, London, Manchester, Newcastle upon Tyne, Oxford, Southampton

2025-06-20

Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

630

Bournemouth, Headington, Leeds, London, Metropolitan Borough of Wirral, Newcastle upon Tyne, Truro

2025-06-11

Active, closed

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 3

Cardiff, Glasgow, Leeds, Leicester, London

2025-06-04

Recruiting

Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study

NCT05881798Deep Vein Thrombosis, Venous Thromboembolism, Pulmonary Embolism

Cook Research Incorporated

Observational

Leeds, Hull, Liverpool

2025-06-02

Active, closed

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

NCT06782373VEXAS, VEXAS Syndrome

DrugPacritinib

Swedish Orphan Biovitrum

Phase 2

156

Leeds, London, Oxford

2025-05-28

Recruiting

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

NCT06876662Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma

DrugPirtobrutinib

Eli Lilly and Company

Phase 4

279

Leeds, Oxford, Plymouth

2025-05-20

Recruiting

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma

DrugPirtobrutinib

Eli Lilly and Company

Phase 4

787

Leeds, Oxford, Plymouth

2025-05-20

Recruiting

A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition

NCT06581146X-Linked Myotubular Myopathy

Astellas Gene Therapies

Observational

Leeds, London, Oxford

2025-05-19

Recruiting

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

NCT06830798Delayed Graft Function, DGF, Kidney Transplant

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

450

Leeds, London, Woodville South

2025-05-19

Recruiting

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785Hepatocellular Carcinoma

DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab

AstraZeneca

Phase 3

1,220

Cambridge, Leeds, London, Manchester

2025-05-06

Recruiting

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

NCT06892548Advanced Lung Cancer

DrugsBNT324·Pumitamig

BioNTech SE

Phase 1/2

594

Bristol, Leeds, Liverpool, London, Manchester, Preston

2025-05-02

Active, closed

Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation

NCT06990529PIDs Linked to PI3K

DrugLeniolisib

Pharming Technologies B.V.

Phase 2

Leeds

2025-04-29

Recruiting

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer

DrugPumitamig

BioNTech SE

Phase 1/2

380

Cambridge, Cardiff, Leeds, London, Manchester, Sutton

2025-04-23

Recruiting

FORWARD CAD IDE Study

NCT06662500Coronary Arterial Disease (CAD)

Shockwave Medical, Inc.

Not applicable

408

Basildon, Bristol, Leeds, Leicester, London

2025-04-04

Recruiting

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06980116Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL)

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Phase 1

Leeds, Plymouth

2025-03-31

Recruiting

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

NCT06750289Eosinophilic Asthma

AstraZeneca

Phase 3

400

Belfast, Birmingham, Bradford, Bristol, Chorley, Leeds, Liverpool, Nottingham

2025-03-28

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

Bath, Cambridge, Leeds, London, Manchester, Northwood, Taunton

2025-03-27

Recruiting

A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours

NCT06977737Solid Tumor, Adult

Accession Therapeutics Limited

Phase 1/2

Glasgow, Cardiff, Leeds, Oxford

2025-03-21

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

565

Leeds, Bristol, Cardiff, London, Southampton

2025-03-20

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Bradford, Brighton, Cottingham, Glasgow, Halifax, Leeds, Portsmouth, Tyne and Wear

2025-03-18

Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354Triple Negative Breast Neoplasms

DrugsAbraxane·Sacituzumab tirumotecan·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,000

Truro, London, Nottingham, Taunton, Birmingham, Cardiff, Leeds

2025-03-16

Active, closed

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT06795048Neovascular Age-related Macular Degeneration (nAMD)

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Phase 4

274

Cardiff, Leeds, Liverpool, London, Newcastle upon Tyne, Wolverhampton

2025-03-14

Recruiting

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

NCT06841055Non-small Cell Lung Cancer

DrugsPumitamig·Docetaxel

BioNTech SE

Phase 2

Cardiff, Leeds, London, Manchester

2025-03-03

Recruiting

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06722235Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

171

Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London

2025-02-27

Recruiting

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer

DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

726

Birmingham, Cardiff, Dundee, Hull, Leeds, London, Londonderry, Manchester

2025-02-27

Recruiting

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

NCT06747949Sjögren's Syndrome

DrugDazodalibep

Amgen

Phase 3

844

Portsmouth, Leeds, London

2025-02-25

Active, closed

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

Leeds, London, Manchester

2025-02-19

Recruiting

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505Chronic Migraine

DrugAtogepant

AbbVie

Phase 3

420

London, Gillingham, Aberdeen, Leeds, Stockport

2025-02-13

Active, closed

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

NCT06843239Systemic Sclerosis (SSc), Scleroderma

Zura Bio Inc

Phase 2

Aberdeen, Bath, Dundee, Leeds, Liverpool, London, Stoke-on-Trent

2025-02-06

Recruiting

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

NCT06754852Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3

Hemab ApS

Phase 1/2

108

Basingstoke, Tooting, Whitechapel, Birmingham, Cardiff, Leeds, Liverpool, London

2025-02-06

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Aberdeen, Birmingham, Cambridge, Glasgow, Leeds, Liverpool, London, Manchester

2025-01-28

Recruiting

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

NCT06697184Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 1/2

258

Birmingham, Leeds

2025-01-23

Recruiting

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774Chronic Graft-versus-host-disease

DrugsAxatilimab·Methylprednisolone·Prednisolone·Prednisone

Incyte Corporation

Phase 3

240

Bristol, Glasgow, Leeds, London, Manchester, Nottingham, Plymouth

2025-01-21

Recruiting

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugPirtobrutinib

Loxo Oncology, Inc.

Phase 2

249

Birmingham, Glasgow, Harrow, Leeds, Lincoln, Liverpool, London, Maidstone

2025-01-03

Recruiting

Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old

NCT06769633Duchenne Muscular Dystrophy

Italfarmaco

Phase 2

Leeds, London, Newcastle upon Tyne, Oxford

2025-01-02

Recruiting

LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.

NCT06514612Acquired Blepharophimosis

Santen SAS

Phase 3

234

Leeds, London, Sunderland

2024-12-30

Active, closed

A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

NCT06718101Atopic Dermatitis

DrugLutikizumab

AbbVie

Phase 2

Bath, Leeds, Liverpool

2024-12-19

Recruiting

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

NCT06716606Connective Tissue Diseases

DrugBelimumab

GlaxoSmithKline

Phase 3

514

Leeds, London

2024-12-12

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Birmingham, Hull, Leeds, London, Northwood

2024-12-12

Recruiting

DERMATOMICS: Identifying Regulators of Skin Homeostasis

NCT06894654Systemic Sclerosis (SSc)

Relation Therapeutics

Observational

500

Leeds, London

2024-12-10

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Cambridge, Doncaster, Greater London, Leeds, Liverpool, London, Peterborough, Swindon

2024-12-04

Active, closed

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06669754Hereditary Angioedema (HAE)

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 3

London, Birmingham, Bristol, Cambridge, Frimley, Leeds, Oxford, Plymouth

2024-12-01

Active, closed

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

NCT06543914Migraine

AbbVie

Observational

1,314

Hull, Edinburgh, London, Nottingham, Stoke-on-Trent, Leeds, Swindon, Worcester

2024-11-26

Active, closed

RCT on the Performance and Safety of LightForce® Therapy Lasers on Knee Osteoarthritis Pain Reduction (SPARK)

NCT06654739Osteoarthritis of Knee

DJO UK Ltd

Not applicable

Leeds

2024-11-23

Recruiting

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

450

Bath, Belfast, Leeds, London, Newcastle upon Tyne, Sheffield, West Bromwich

2024-11-21

Active, closed

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

NCT06460506Cystic Fibrosis

DrugsELX/TEZ/IVA·Ivacaftor·Elexacaftor/Tezacaftor/Ivacaftor

Vertex Pharmaceuticals Incorporated

Phase 3

Cardiff, Leeds, Liverpool, London, Southampton

2024-11-21

Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

NCT06655155Systemic Sclerosis (SSc)

argenx

Phase 2

Leeds, London, Luton

2024-11-11

Active, closed

A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy

NCT06713135Duchenne Muscular Dystrophy

DrugVamorolone

Santhera Pharmaceuticals

Phase 4

Glasgow, Liverpool, Leeds, Birmingham, London, Newcastle

2024-11-10

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

680

Bristol, London, Nottingham, Leeds, Leicester, Manchester, Metropolitan Borough of Wirral, Portsmouth

2024-10-21

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Cetuximab

Janssen Research & Development, LLC

Phase 3

1,000

Birmingham, Cambridge, Edinburgh, Hull, Leeds, London, Northwood, Sutton

2024-10-18

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089Arthritis, Psoriatic

DrugsSonelokimab·Risankizumab

MoonLake Immunotherapeutics AG

Phase 3

600

Westcliff-on-Sea, Barnet, Leeds, Wolverhampton

2024-10-15

Active, closed

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564Chronic Graft-versus-host-disease

DrugsAxatilimab·Ruxolitinib·Methylprednisolone·Prednisolone

Incyte Corporation

Phase 2

130

Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool

2024-10-11

Active, closed

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

NCT05417789TGCT

DrugEmactuzumab

SynOx Therapeutics Limited

Phase 3

128

Leeds, London

2024-10-09

Active, closed

Development of a New Patient Reported Outcome Measure (PROM) to Assess Patient's Emotional Wellbeing, and Perceptions of Total Knee Replacement Surgery for the Treatment of Knee Arthritis

NCT06585267Complete Questionnaires Following TKR Surgery

Invibio Ltd

Observational

167

Leeds

2024-10-07

Active, closed

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Adagrasib·Sotorasib

Hoffmann-La Roche

Phase 3

338

Cambridge, Cottingham, Glasgow, Leeds, London, Nottingham, Sutton, Torquay

2024-09-23

Active, closed

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279Myasthenia Gravis, Ocular

argenx

Phase 3

141

Brighton, Glasgow, Leeds, London, Southampton

2024-09-18

Active, closed

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

NCT06571383Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 4

500

Birmingham, Bristol, Leeds, Liverpool, London, Sheffield, Southampton

2024-09-17

Recruiting

A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

NCT06547840Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Triple -Negative Breast Cancer

Epsilogen Ltd

Phase 1

Bristol, Edinburgh, Leeds, London, Southampton

2024-09-03

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

Birmingham, Cambridge, Leeds, Leicester, London, Northwood

2024-08-28

Active, closed

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers

DrugsEribulin·Pumitamig·Gemcitabine·Paclitaxel

BioNTech SE

Phase 2

Cottingham, Edinburgh, Leeds, London

2024-08-26

Recruiting

Observational Study of Venus P-Valve

NCT05835349Right Ventricular Outflow Tract Dysfunction

Venus MedTech (HangZhou) Inc.

Observational

200

Leeds, London

2024-08-26

Active, closed

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498Multiple Myeloma

DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib

Kite, A Gilead Company

Phase 3

452

Bristol, Cardiff, Leeds, London, Newcastle

2024-08-23

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Birmingham, Dundee, Glasgow, Greater London, Leeds, London

2024-08-12

Active, closed

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

NCT06449209Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer

DrugsPumitamig·Topotecan·Etoposide·Paclitaxel

BioNTech SE

Phase 2

110

Birmingham, Cardiff, Dundee, Exeter, Huddersfield, Leeds, London, Newcastle upon Tyne

2024-08-05

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

London, Sutton, Glasgow, Leeds, Manchester

2024-07-24

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

976

Bristol, Cambridge, Edinburgh, Glasgow, High Wycombe, Leeds, London, North Finchley

2024-07-19

Recruiting

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

NCT06481306Anemia, Sickle Cell, Healthy Volunteers

DrugsFamotidine·Pantoprazole

Bristol-Myers Squibb

Phase 1/2

224

East Sussex, London, Leeds

2024-07-17

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Cambridge, Leeds, London, Newcastle upon Tyne

2024-06-29

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6

Boehringer Ingelheim

Phase 1/2

768

Cardiff, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Sutton

2024-06-28

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Bristol, Hills Road, Truro, London, Edinburgh, Leeds

2024-06-24

Recruiting

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

NCT06439277Obesity, Weight Gain

DrugTirzepatide

Eli Lilly and Company

Phase 3

300

Cambridge, Glagow, Leeds, Leicester, Liverpool, London, Newcastle upon Tyne, Sheffield

2024-06-03

Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

DrugPegozafermin

89bio, Inc.

Phase 3

762

Aberdeen, Bristol, Leeds, London, Oxford, Plymouth, Port Talbot, Portsmouth

2024-05-24

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Cambridge, Edinburgh, London, Nottingham, Leeds, Manchester

2024-05-19

Active, closed

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

DrugNerandomilast

Boehringer Ingelheim

Phase 3

1,666

Aberdeen, Birmingham, Bristol, Edinburgh, Exeter, Lancaster, Leeds, London

2024-05-06

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis

DrugEfgartigimod

argenx

Phase 3

119

Glasgow, Leeds

2024-04-16

Active, closed

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

NCT06245408Sjögren's Syndrome (SS)

DrugDazodalibep

Amgen

Phase 3

434

Leeds, London

2024-04-08

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727Solid Tumor, Adult

DrugsCRB-701·Anti-PD-1

Corbus Pharmaceuticals Inc.

Phase 1/2

348

Birmingham, Cambridge, Cardiff, Leeds, London, Manchester, Metropolitan Borough of Wirral, Southampton

2024-04-01

Recruiting

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

NCT06435000Stargardt, Stargardt's Disease, Stargardt Disease, STGD1

Splice Bio

Observational

London, Leeds, Manchester, Oxford

2024-03-29

Recruiting

Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II

NCT06271577Myocardial Infarction, Ischemia, Myocardial Ischemia, Heart Diseases

AliveCor

Not applicable

1,000

Leeds, Edinburgh

2024-03-12

Active, closed

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118Dermatitis Atopic

DrugsPimecrolimus·Amlitelimab·Tacrolimus

Sanofi

Phase 3

464

Bristol, Plymouth, London, Portsmouth, Leeds, Nottingham, Liverpool

2024-02-29

Active, closed

Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria

NCT06298955Paroxysmal Nocturnal Hemoglobinuria

DrugOMS906 study drug

Omeros Corporation

Phase 2

Leeds

2024-02-19

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744Follicular Lymphoma (FL)

DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine

Genmab

Phase 3

1,095

Plymouth, London, Portsmouth, Leeds, Manchester, Newcastle upon Tyne

2024-02-05

Active, closed

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

NCT06237335Cystic Fibrosis

DrugIvacaftor

ReCode Therapeutics

Phase 2

128

Birmingham, Cambridge, Leeds, London, Nottingham, Southampton

2024-02-01

Recruiting

OSsIRIS Study - A Post-market Clinical Follow-up Investigation.

NCT06156904Surgically Created Bone Defects or Bone Defects/Voids Resulting From Traumatic Injury

GreenBone Ortho S.p.A.

Observational

135

Hull, Leeds

2024-01-31

Active, closed

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06112743Cardiomyopathy, Hypertrophic

DrugMavacamten

Bristol-Myers Squibb

Phase 4

Leeds

2024-01-24

Active, closed

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891Chronic Graft Versus Host Disease

DrugsBelumosudil·Prednisolone·Prednisone

Sanofi

Phase 3

260

Cardiff, London, Leeds, Manchester, Newcastle upon Tyne

2024-01-23

Active, closed

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150Multiple Myeloma

DrugsElotuzumab·Talquetamab·Velcade·Teclistamab

Janssen Research & Development, LLC

Phase 3

838

Blackpool, Cardiff, Dundee, Leeds, London, Nottingham, Plymouth, Portsmouth

2024-01-22

Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

1,264

Aberdeen, Dundee, Huddersfield, Leeds, Manchester, Northwood, Sheffield, Wolverhampton

2023-12-21

Recruiting

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

NCT05912517Hemolytic Disease of the Fetus and Newborn

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

120

Birmingham, Leeds, London, Manchester, Oxford

2023-12-20

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Aberdeen, Cambridge, Hampshire, Leeds, London, Manchester, Metropolitan Borough of Wirral, Northwood

2023-12-14

Active, closed

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

NCT05734105GIST

DrugsRipretinib·Sunitinib

Deciphera Pharmaceuticals, LLC

Phase 3

London, Leeds

2023-12-13

Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsNemtabrutinib·Ibrutinib·Acalabrutinib

Merck Sharp & Dohme LLC

Phase 3

1,200

Bristol, Lancaster, London, Oxford, Newmarket, Windsor, Barnet, Leeds

2023-12-13

Recruiting

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin

AstraZeneca

Phase 2

226

Glasgow, Leeds, London, Oxford

2023-12-13

Active, closed

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06132256Idiopathic Pulmonary Fibrosis

DrugAxatilimab

Syndax Pharmaceuticals

Phase 2

145

Cambridge, Norwich, Oxford, Perth, Leeds, Birmingham

2023-12-11

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

DrugsCamizestrant·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 1/2

564

Cambridge, Leeds, London, Manchester

2023-12-05

Recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

NCT06166056Bronchiectasis

Chiesi Farmaceutici S.p.A.

Phase 1/2

Cambridge, Dundee, Edinburgh, Glasgow, Leeds, London, Manchester, Southampton

2023-11-29

Recruiting

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

NCT05935358Severe Hemophilia A

DrugNuwiq

Octapharma

Phase 4

Leeds

2023-11-28

Active, closed

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

NCT06073821CLL

DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

652

Bournemouth, Canterbury, Headington, Leeds, Liverpool, London, Norwich, Southampton

2023-11-11

Active, closed

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

NCT06097728Unresectable Pleural Mesothelioma

DrugsVolrustomig·Yervoy·Paraplatin·Ipilimumab

AstraZeneca

Phase 3

863

Cambridge, Leeds, Leicester, London, Manchester, Newcastle upon Tyne, Portsmouth, Taunton

2023-11-09

Active, closed

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803Systemic Sclerosis, Scleroderma

AstraZeneca

Phase 3

314

Cannock, Leeds, London, Sheffield

2023-11-08

Active, closed

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT06122779Heart Failure

DrugBMS-986435

Bristol-Myers Squibb

Phase 2

227

Harrow, North Shields, Leeds, Bristol, Dundee, London, Oxford, Stockton-on-Tees

2023-11-07

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626Metastatic Breast Cancer

DrugsAbemaciclib·Fulvestrant

LeonaBio

Phase 3

600

Cardiff, Harlow, Leeds, London, Manchester, Milton Keynes, Nottingham, Stockton-on-Tees

2023-10-31

Active, closed

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915Sjogrens Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

612

Doncaster, Leeds, Liverpool, Newcastle upon Tyne, Swindon

2023-10-27

Active, closed

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

1,600

Leeds, London, Manchester

2023-10-26

Recruiting

ZNN Bactiguard Retrograde Femoral Nails PMCF Study

NCT05276674Femoral Fracture

Zimmer Biomet

Observational

100

Leeds, Manchester, Stockport

2023-10-23

Active, closed

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 2

114

Bournemouth, Glasgow, Headington, Inverness, Leeds, London, Manchester, Plymouth

2023-10-23

Active, closed

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

NCT05598333Congestive Heart Failure

AskBio Inc

Phase 2

150

Manchester, Leeds, Cardiff, Glasgow, London

2023-10-20

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

Aberdeen, Burton-on-Trent, Cambridge, Derby, Guildford, Ipswich, Lancaster, Leeds

2023-10-05

Active, closed

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

NCT06007677Hereditary Angioedema

DrugNavenibart

Astria Therapeutics, Inc.

Phase 2

Cambridge, Leeds

2023-09-26

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Barnet, Blackpool, Canterbury, Exeter, Glasgow, Leeds, London, Newcastle

2023-09-18

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic

DrugBelimumab

GlaxoSmithKline

Phase 2/3

300

Wakefield, Birmingham, Leeds, London, Portsmouth

2023-09-13

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617Primary Biliary Cholangitis

DrugSeladelpar

Gilead Sciences

Phase 3

402

Hull, Ipswich, Leeds, London, Newcastle upon Tyne, Oxford, Sheffield, Wolverhampton

2023-09-07

Recruiting

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

NCT06126224Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

500

Ilford, Swinton, London, Aberdeen, Chertsey, Edinburgh, Leeds, Motherwell

2023-08-28

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Bristol, Cambridge, Cringleford, London, Edinburgh, Oxford, Leeds, Manchester

2023-07-19

Recruiting

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

NCT05980949Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1,000

Ilford, Swinton, Aberdeen, Chertsey, Leeds, Motherwell, Preston, Sheffield, SouthYorkshire

2023-07-11

Active, closed

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

NCT05726227Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 3

212

Birmingham, Bristol, Leeds, Liverpool, Southampton

2023-07-07

Active, closed

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

NCT05966480SLE

DrugEnvudeucitinib

Alumis Inc

Phase 2

408

Leeds, London, Southampton

2023-06-26

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

London, Southampton, Coventry, Leeds, Bristol, Salford

2023-06-21

Active, closed

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

NCT05926765Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands

MeiraGTx, LLC

Phase 2

290

Cambridge, Cardiff, Dundee, Glasgow, Leeds, London, Nottingham, York

2023-06-13

By invitation

An Open-label Study of XEN1101 in Epilepsy

NCT05718817Focal Epilepsy, Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

880

Leeds, Cardiff, Birmingham, London, Oxford, Salford

2023-04-25

Active, closed

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

NCT05624749Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

288

Leeds, Doncaster

2023-04-21

Active, closed

Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab

NCT05626855Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA

DrugApitegromab

Scholar Rock, Inc.

Phase 3

238

Leeds, London, Oxford

2023-04-17

Active, closed

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma

AbbVie

Phase 1

Leeds, London, Manchester

2023-04-04

Active, closed

Study of Novel Treatment Combinations in Patients With Lung Cancer

NCT05633667Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer

DrugsDomvanalimab·Zimberelimab·Sacituzumab Govitecan·Nab-paclitaxel

Gilead Sciences

Phase 2

192

Birmingham, Leeds, London

2023-03-16

Recruiting

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

NCT05744921Paroxysmal Nocturnal Hemoglobinuria

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

202

Leeds

2023-03-07

Active, closed

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma

DrugsTovorafenib·Carboplatin

Day One Biopharmaceuticals, Inc.

Phase 3

418

Birmingham, Leeds, Liverpool, Manchester, Newcastle upon Tyne, Oxford, Southampton, Belfast

2023-02-27

Recruiting

Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

NCT05496998Mitral Regurgitation

Medtronic Cardiovascular

Not applicable

400

Brighton, Leeds, London

2023-02-07

Active, closed

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

NCT05686551Huntington Disease

Hoffmann-La Roche

Phase 2

301

Birmingham, Cambridge, Leeds, London, Oxford, Southampton

2023-02-03

Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

NCT05580562H3 K27M, Glioma

DrugDordaviprone

Jazz Pharmaceuticals

Phase 3

510

Cambridge, Glasgow, Liverpool, Manchester, Sutton, Newcastle upon Tyne, Leeds, London

2023-01-23

Recruiting

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05702229Gastric Cancer

DrugsSonesitatug Vedotin·Volrustomig·Xelox·Rilvegostomig

AstraZeneca

Phase 2

163

Edinburgh, Leeds, London, Oxford

2023-01-16

Active, closed

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Carfilzomib·Dexamethasone

Bristol-Myers Squibb

Phase 3

606

Plymouth, Cringleford, Glasgow, Birmingham, Leeds, Taunton

2023-01-10

Active, closed

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

Birmingham, Leeds, London

2022-12-30

Active, closed

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

NCT05024773Bladder Carcinoma in Situ (CIS)

Fidia Farmaceutici s.p.a.

Phase 3

130

Dartford, Huddersfield, Leeds, London, Plymouth, Preston, Sutton

2022-12-29

Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297Advanced Melanoma

DrugTebentafusp

Immunocore Ltd

Phase 3

540

Cambridge, Manchester, Birmingham, Leeds, London, Middlesex, Sutton

2022-12-19

Active, closed

A Study of Daratumumab

NCT05438043Multiple Myeloma

DrugsCarfilzomib·Pomalidomide·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

213

Leeds, Leicester, Surrey, Wolverhampton

2022-12-15

Active, closed

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

NCT06211634Glanzmann Thrombasthenia

Hemab ApS

Phase 1/2

Birmingham, Leeds, London, Whitechapel

2022-12-13

Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450Viral Lung Infection and Acute Respiratory Failure

DrugTozorakimab

AstraZeneca

Phase 3

3,527

Bristol, Dundee, Glasgow, Hampshire, Huddersfield, Leeds, Leicester, London

2022-12-13

Active, closed

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

822

Birmingham, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Leeds, Liverpool

2022-11-08

Active, closed

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

NCT05389449Paroxysmal Nocturnal Hemoglobinuria

DrugDanicopan

Alexion Pharmaceuticals, Inc.

Phase 3

Airdrie, Leeds, London

2022-10-28

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Herceptin·Erbitux·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

Newcastle upon Tyne, Glasgow, Sutton, Bristol, Cambridge, Leeds, London, Manchester

2022-10-24

Recruiting

Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease

NCT05659901Pelizaeus-Merzbacher Disease

Ionis Pharmaceuticals, Inc.

Observational

Leeds

2022-10-03

Active, closed

NCT05409066Follicular Lymphoma (FL)

DrugsEpcoritamab·Lenalidomide·Rituximab

Genmab

Phase 3

549

Plymouth, Glasgow, London, Oxford, Leeds, Birmingham, Colchester, Liverpool

2022-09-20

Active, closed

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 2/3

450

London, Manchester, Birmingham, Leeds

2022-09-13

Recruiting

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

NCT05489705Obstructive Hypertrophic Cardiomyopathy

DrugMavacamten

Bristol-Myers Squibb

Observational

1,700

London, Manchester, Liverpool, Birmingham, Leeds, Cardiff

2022-08-16

Active, closed

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

NCT05524883Duchenne Muscular Dystrophy (DMD)

DrugZeleciment Rostudirsen

Dyne Therapeutics

Phase 1/2

Liverpool, Newcastle upon Tyne, Leeds, Bristol, London

2022-08-12

Active, closed

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214Sjogren Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

506

Doncaster, Leeds, Liverpool, Newcastle upon Tyne, Swindon

2022-08-04

Active, closed

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

NCT05489237Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases

DrugIDRX-42

IDRX, Inc., a wholly owned subsidiary of GSK, LLC

Phase 1

276

Leeds, London

2022-08-03

Active, closed

A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

NCT05133531Paroxysmal Nocturnal Hemoglobinuria

DrugsSoliris·Ultomiris·Cemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

202

Leeds

2022-08-01

Active, closed

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286Triple Negative Breast Cancer, PD-L1 Positive

DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel

Gilead Sciences

Phase 3

443

Edinburgh, Glasgow, Leeds, London, Nottingham

2022-07-25

Active, closed

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299Triple Negative Breast Cancer, PD-L1 Negative

DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine

Gilead Sciences

Phase 3

623

Leeds, London

2022-07-20

Active, closed

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

NCT05352672Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,546

Exeter, Cottingham, Leeds, Guildford

2022-07-14

Active, closed

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 3

586

Birmingham, Glasgow, Leeds, Leicester, London, Manchester, Wolverhampton

2022-07-08

Recruiting

International Wilson's Disease Patient Registry (iWilson Registry)

NCT05239858Wilson's Disease

Orphalan

Observational

500

Leeds, London

2022-06-29

Recruiting

First in Human Study of T3P-Y058-739 (T3P)

NCT05120596Advanced Solid Tumor

DrugPembrolizumab

T3 Pharmaceuticals AG

Phase 1/2

100

Glasgow, Leeds, London, Southampton

2022-04-26

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)

DrugBexobrutideg

Nurix Therapeutics, Inc.

Phase 1

572

Manchester, Glasgow, Leeds, Liverpool, London, Oxford, Plymouth, Southampton

2022-04-13

Recruiting

Zimmer® Natural Nail® (ZNN) Bactiguard Tibia Post-Market Clinical Follow-up Study

NCT05022485Tibial Fractures, Fracture Infection

Zimmer Biomet

Observational

500

Edinburgh, Leeds, London

2022-04-11

Recruiting

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease

NCT05318534First in Man Study to Evaluate Initial Safety

Gliknik Inc.

Phase 1

Leeds

2022-04-08

Active, closed

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

NCT05270668Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease

DrugTulisokibart

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

154

London, Leeds

2022-03-29

Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

NCT04895436Chronic Lymphocytic Leukemia (CLL)

DrugsVenclexta·Obinutuzumab·Venetoclax

AbbVie

Phase 2

Blackpool, Norwich, Leeds

2022-03-28

Active, closed

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 3

799

Glasgow, Greater Manchester, Huddersfield, Inverness, Leeds, London, Plymouth, Southampton

2022-03-10

Active, closed

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

NCT05211895Non-Small Cell Lung Cancer

DrugsDomvanalimab·Durvalumab

AstraZeneca

Phase 3

791

Birmingham, Brighton, Cardiff, Cheltenham, Edinburgh, High Heaton/Newcastle Upon Tyn, Leeds, London

2022-02-18

Active, closed

Clinical Impact of the IBox As an Early Intervention TooL

NCT05112315Kidney Diseases, Kidney Disease, Chronic, Kidney Transplant Rejection, Kidney Transplant; Complications

Predict4Health

Not applicable

507

Birmingham, Leeds, London, Oxford

2022-02-18

Active, closed

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD

DrugsEylea·Aflibercept

AbbVie

Phase 3

735

Aylesbury, London, Gloucester, Southampton, Oxford, Leeds, Bradford, Bristol

2022-01-13

Recruiting

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

NCT05037760Myelofibrosis

DrugsElritercept·Ruxolitinib

Takeda

Phase 2

135

Boston, Leeds, London

2021-12-16

Active, closed

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

NCT05002777Warm Autoimmune Hemolytic Anemia (wAIHA)

DrugRilzabrutinib

Sanofi

Phase 2

Leeds, London

2021-12-07

Active, closed

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZanidatamab·Herceptin·Trastuzumab·Adrucil

Jazz Pharmaceuticals

Phase 3

920

Bristol, Edinburgh, Leeds, London, Peterborough, Sheffield

2021-12-02

Active, closed

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

NCT05091567Small-Cell Lung Cancer

DrugsLurbinectedin·Tecentriq·Etoposide·Atezolizumab

Hoffmann-La Roche

Phase 3

660

Blackpool, GB Manchester, Hull, Leeds, Leicester, London

2021-11-18

Active, closed

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05089734Non-Small Cell Lung Cancer

DrugsSacituzumab Govitecan·Docetaxel

Gilead Sciences

Phase 3

603

Birmingham, Colchester, Glasgow, Leeds, Leicester, London, Manchester

2021-11-17

Recruiting

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

NCT04996875Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)

DrugBezuclastinib

Cogent Biosciences, Inc.

Phase 2

140

Leeds, London

2021-11-09

Recruiting

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

NCT05065216Acute Stroke, Ischemic Stroke, Stroke

DiaMedica Therapeutics Inc

Phase 2/3

728

Exeter, Newcastle upon Tyne, Cambridge, London, Stoke-on-Trent, Kirkcaldy, Leeds, Middlesbrough

2021-11-07

Active, closed

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

NCT04963296Systemic Lupus Erythematosus

DrugsAcetaminophen/paracetamol·Diphenhydramine hydrochloride·Methylprednisolone·Obinutuzumab

Hoffmann-La Roche

Phase 3

303

Cambridge, Leeds, London, Manchester

2021-10-26

Active, closed

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

600

Birmingham, Leeds, Leicester, London, Oxford, Plymouth

2021-09-20

Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma

DrugTacabrutideg

BeOne Medicines

Phase 1/2

689

Edinburgh, Leeds, Newcastle upon Tyne, Newmarket, Norwich, Nottingham, Plymouth

2021-09-13

Active, closed

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210Arthritis, Psoriatic

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 4

411

Barnet, Bradford, Coventry, Leeds, Manchester, Newcastle, Stoke-on-Trent

2021-08-30

Active, closed

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

NCT05049798Arthritis, Psoriatic

DrugsIL-17i·Tremfya·Guselkumab

Janssen Pharmaceutica N.V., Belgium

Observational

1,314

Aberdeen, Abergavenny, Airdrie, Barnet, Bath, Glasgow, Hull, Leeds

2021-08-25

Active, closed

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893Multiple Myeloma

DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine

Janssen Research & Development, LLC

Phase 3

743

Birmingham, Bristol, Leeds, London, Manchester, Surrey

2021-08-19

Active, closed

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT04747613Paroxysmal Nocturnal Hemoglobinuria

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

208

Leeds, London

2021-07-27

Active, closed

Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing

NCT04798768Tachycardia, Ventricular, Arrhythmia, Ventricular

Boston Scientific Corporation

Not applicable

297

Leeds, Liverpool, Manchester, Southampton

2021-07-20

Active, closed

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

NCT04969835Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer

Avacta Life Sciences Ltd

Phase 1

158

Glasgow, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield

2021-07-16

Active, closed

Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation

NCT04788888Symptomatic Severe Aortic Stenosis

Abbott Medical Devices

Not applicable

434

Swansea, Belfast, Leeds, London

2021-07-13

Active, closed

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755Neoplasms, Breast

DrugNiraparib

GlaxoSmithKline

Phase 3

Bath, Brighton, Cardiff, Coventry, Edinburgh, Leeds, London, Maidstone

2021-06-28

Active, closed

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer

DrugsAdagrasib·MFOLFOX6·Erbitux·Folfox

Mirati Therapeutics Inc.

Phase 3

461

Aberdeen, Birmingham, Cambridge, Dorset, Glasgow, Kent, Leeds, London

2021-06-24

Active, closed

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

NCT04877691Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

367

Doncaster, Leeds, London

2021-06-08

Active, closed

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK)

NCT04573881Liver Neoplasms, Hepatocellular Carcinoma, Liver Metastases

HistoSonics, Inc.

Not applicable

Leeds, Newcastle

2021-06-04

Recruiting

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NCT04811560Acute Leukemia

DrugBleximenib

Janssen Research & Development, LLC

Phase 1/2

420

Cardiff, Leeds, Liverpool, London, Manchester, Oxfordshire, Plymouth

2021-05-19

Active, closed

SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial

NCT04722250Symptomatic Aortic Stenosis, Aortic Valve Stenosis, Aortic Valve Replacement

Medtronic Cardiovascular

Not applicable

1,103

Edinburgh, Leeds

2021-04-02

Recruiting

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma

DrugsNavtemadlin·Acalabrutinib

Kartos Therapeutics, Inc.

Phase 1/2

Leeds, London, Southampton

2021-02-23

Active, closed

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04408638Diffuse Large B-cell Lymphoma

DrugsRituxumab·Glofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

270

Glasgow, Leeds, London, Manchester, Nottingham

2021-02-23

Active, closed

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Palbociclib

AstraZeneca

Phase 3

1,371

Cambridge, Colchester, Leeds, Nottingham, Surrey

2021-01-28

Active, closed

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer

DrugPembrolizumab

BioNTech SE

Phase 2/3

358

Aberdeen, Belfast, Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool

2021-01-07

Active, closed

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 2

220

Glasgow, Leeds

2020-12-18

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

NCT04663308Primary Sclerosing Cholangitis

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

182

London, Oxford, Belfast, Birmingham, Cambridge, Edinburgh, Leeds, Newcastle upon Tyne

2020-12-18

Active, closed

Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

NCT04794101X-Linked Retinitis Pigmentosa

MeiraGTx Ocular UK Ltd

Phase 3

Edinburgh, Glasgow, Leeds, London

2020-12-04

Active, closed

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

NCT04540497IgG4 Related Disease

DrugInebilizumab

Amgen

Phase 3

135

Leeds, London, Newcastle, Oxford

2020-12-04

Active, closed

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

DrugsTrastuzumab emtansine·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 3

1,600

Peterborough, Maidstone, Manchester, Metropolitan Borough of Wirral, Nottingham, Bath, Taunton, Leeds

2020-12-04

Active, closed

A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

NCT04434092Paroxysmal Nocturnal Hemoglobinuria

DrugsCrovalimab·Eculizumab

Hoffmann-La Roche

Phase 3

210

Leeds, London

2020-10-08

Active, closed

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Advanced or Metastatic Breast Cancer

DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel

AstraZeneca

Phase 3

866

Cambridge, Cardiff, Edinburgh, Guildford, Leeds, London, Manchester, Northwood

2020-07-24

Active, closed

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

NCT03992430Muscular Dystrophy, Duchenne

DrugEteplirsen

Sarepta Therapeutics, Inc.

Phase 3

160

Leeds, Birmingham, London

2020-07-13

Active, closed

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

NCT04380636Lung Neoplasms, Carcinoma, Non-Small-Cell Lung

DrugsParaplatin·Taxol·Olaparib·Etoposide

Merck Sharp & Dohme LLC

Phase 3

870

Sheffield, London, London-Camden, Southampton, Leeds, Manchester

2020-07-06

Active, closed

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

NCT04478279Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer

DrugTemozolomide

Sapience Therapeutics

Phase 1/2

125

Edinburgh, Glasgow, Leeds, London

2020-07-01

Active, closed

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

NCT04277637Mature B-Cell Malignancies

DrugsSonrotoclax·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 1

437

Leeds

2020-03-24

Active, closed

A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

NCT04170283B-cell Malignancies

DrugsZanubrutinib·Tislelizumab

BeOne Medicines

Phase 3

955

Aberdeen, Birmingham, Bournemouth, Canterbury, Glasgow, Greater Manchester, Headington, Leeds

2020-01-16

Recruiting

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

NCT03969329Secondary Hyperparathyroidism

DrugEtelcalcetide

Amgen

Phase 3

Glasgow, Leeds, London, Southampton

2019-12-20

Active, closed

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

NCT04180371Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer

DrugsNuzefatide pevedotin·Opdivo·Nivolumab

BicycleTx Limited

Phase 1/2

288

London, Manchester, Cambridge, Leeds, Newcastle upon Tyne

2019-11-07

Active, closed

SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

NCT04079166Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV

DrugsDNA vaccine·ImmunoBody

Scancell Ltd

Phase 2

173

Cambridge, Cardiff, Leeds, London, Manchester, Northwood, Nottingham, Oxford

2019-08-19

Active, closed

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

NCT04119050Warm Autoimmune Hemolytic Anemia

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

118

Leeds, Liverpool, London, Oxford, Plymouth, Southampton

2019-08-15

Recruiting

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

DrugLuspatercept

Celgene

Phase 3

665

Aberdeen, Leeds, London, Oxford, Sutton in Ashfield

2019-08-12

Recruiting

Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

NCT04029363Mitral Regurgitation

HighLife SAS

Not applicable

120

Belfast, Brighton, Edinburgh, Leeds, Leicester, London, Oxford

2019-05-28

Recruiting

Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator

NCT03876054Chronic Pain

Abbott Medical Devices

Observational

2,000

Norwich, Liverpool, Bristol, Leeds

2019-03-13

Active, closed

Durvalumab and Tremelimumab for Pediatric Malignancies

NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies

DrugDurvalumab

AstraZeneca

Phase 1/2

Leeds, London, Sutton

2019-03-07

Active, closed

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154Carcinoma, Non-Small-Cell Lung

DrugDurvalumab

AstraZeneca

Phase 3

724

Birmingham, Leeds, London, Manchester

2019-03-06

Active, closed

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

NCT03673501Gastrointestinal Stromal Tumors

DrugsRipretinib·Sunitinib

Deciphera Pharmaceuticals, LLC

Phase 3

453

Glasgow, Leeds, London, Sheffield

2019-02-08

Active, closed

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

NCT03616587ER+ HER2- Advanced Breast Cancer

DrugCamizestrant

AstraZeneca

Phase 1

396

Cambridge, Leeds, London, Manchester, Sutton

2018-10-11

Active, closed

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318Atopic Dermatitis

DrugUpadacitinib

AbbVie

Phase 3

1,533

London, Oxford, Dundee, Glasgow, Leeds

2018-08-09

Recruiting

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

NCT02991469Juvenile Idiopathic Arthritis

DrugSarilumab

Sanofi

Phase 2

London, Leeds, Liverpool

2018-08-09

Recruiting

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796Neoplasms

Celgene

Phase 2/3

1,541

Leeds, London, Manchester Withington, Shirley Southampton

2018-07-19

Active, closed

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Folinic acid·Fluorouracil·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

565

Aberdeen, London, Sutton, Cambridge, Coventry, Dundee, Leeds, Manchester

2018-06-21

Active, closed

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

NCT03522246Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed

DrugsRucaparib·Opdivo·Nivolumab

pharmaand GmbH

Phase 3

1,097

Canterbury, Cliftonville, Brighton, Bristol, Cambridge, Edinburgh, Lancaster, Leeds

2018-05-14

Active, closed

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell

DrugsChlorambucil·Ibrutinib·Obinutuzumab·Venetoclax

Janssen Research & Development, LLC

Phase 3

211

Birmingham, Cambridge, Charterhouse Square, Glasgow, Leeds, Plymouth, Romford, Sheffield

2018-04-17

Active, closed

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT03363373Neuroblastoma

DrugsNaxitamab·Gm-Csf

Y-mAbs Therapeutics

Phase 2

122

Glasgow, Leeds, Southampton

2018-04-03

Active, closed

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

NCT03423628Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)

DrugAZD1390

AstraZeneca

Phase 1

159

Cambridge, Glasgow, Leeds

2018-04-02

Active, closed

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT03328273Chronic Lymphocytic Leukemia

DrugsCeralasertib·Acalabrutinib

Acerta Pharma BV

Phase 1

Birmingham, Bournemouth, Cardiff, Leeds, London, Nottingham, Oxford, Southampton

2018-01-31

Recruiting

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

NCT03142152Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases

Cardiac Dimensions, Inc.

Not applicable

300

Leeds

2018-01-01

Active, closed

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

NCT03336333Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsVenclyxto·Bendamustine·Venclexta·Zanubrutinib

BeiGene

Phase 3

590

Birmingham, Bournemouth, Cambridge, Canterbury, Greater Manchester, Leeds, London, Maidstone

2017-10-31

Active, closed

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma

DrugsVusolimogene Oderparepvec·Opdivo·Nivolumab

Replimune, Inc.

Phase 2

340

Leeds, Oxford, Glasgow, Bebington, London, Southampton

2017-09-20

Active, closed

ATTUNE® Revision- Complex Primary in Total Knee Arthroplasty Population

NCT03153449Primary Knee Arthroplasty

DePuy Orthopaedics

Not applicable

400

Basingstoke, Kirkcaldy, Leeds, Middlesbrough, Oswestry, Oxford, Wigan

2017-09-19

Active, closed

ATTUNE Revision System in the Revision Total Knee Arthroplasty Population

NCT03153475Revision Total Knee Arthroplasty

DePuy Orthopaedics

Not applicable

400

Basingstoke, Kirkcaldy, Leeds, North Yorks, Oswestry, Oxford, Wigan

2017-05-30

Active, closed

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

NCT03229200Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease

DrugIbrutinib

Pharmacyclics Switzerland GmbH

Phase 4

297

Cardiff, Leeds, London, Manchester

2017-05-22

Active, closed

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030Multiple Myeloma

DrugsIberdomide·Darzalex·Velcade·Carfilzomib

Celgene

Phase 1/2

466

Birmingham, Leeds, Oxford, Sutton

2016-10-14

Active, closed

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

NCT02811861Renal Cell Carcinoma

DrugsSunitinib·Everolimus·Lenvatinib·Pembrolizumab

Eisai Inc.

Phase 3

1,069

Bournemouth, Cardiff, Edinburgh, Glasgow, Leeds, London, Manchester

2016-10-13

Active, closed

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

NCT02717611Chronic Lymphocytic Leukemia

DrugAcalabrutinib

Acerta Pharma BV

Phase 2

Bournemouth, Leeds, Manchester

2016-03-08

Active, closed

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT02598661Myelodysplastic Syndromes

DrugImetelstat Sodium

Geron Corporation

Phase 2/3

289

Leeds, Nottingham, Southampton, Aberdeen

2016-01-12

Active, closed

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

NCT02516241Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,126

Cambridge, Cardiff, Glasgow, Leeds, London, Manchester, Metropolitan Borough of Wirral, Sheffield

2015-11-02

Active, closed

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

NCT02477696Chronic Lymphocytic Leukemia

DrugsIbrutinib·Acalabrutinib

Acerta Pharma BV

Phase 3

533

Birmingham, Bournemouth, Cambridge, Cardiff, Greater London, Hull, Leeds, Leicester

2015-07-28

Active, closed

Micra Transcatheter Pacing System Post-Approval Registry

NCT02536118Bradycardia

Medtronic

Observational

3,100

Birmingham, Bristol, Leeds, Leicester, Liverpool, London, Manchester, Middlesbrough

2015-07

Active, closed

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

NCT02475681Chronic Lymphocytic Leukemia

DrugsChlorambucil·Acalabrutinib·Obinutuzumab

Acerta Pharma BV

Phase 3

535

Bournemouth, Cambridge, Leeds, Leicester, London, Plymouth, Southampton, Truro

2015-06-26

Active, closed

Transcatheter Mitral Valve Replacement System (TMVR) Pilot Study and The Early Feasibility Study of the TMVR Transseptal System

NCT02322840Mitral Valve Insufficiency

Medtronic Cardiovascular

Not applicable

128

Brighton, Leeds, London

2015-04

Active, closed

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

NCT02213926Mantle Cell Lymphoma (MCL)

DrugAcalabrutinib

Acerta Pharma BV

Phase 2

124

Cardiff, Leeds, Leicester, Nottingham, Oxford, Plymouth, Southampton

2015-03-02

Active, closed

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02227251Diffuse Large B-cell Lymphoma

DrugSelinexor

Karyopharm Therapeutics Inc

Phase 2

244

Gloucester, Southampton, Sutton, Harrow, Leeds, Cambridge, Liverpool, London

2014-11

Active, closed

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

NCT02180724Waldenström Macroglobulinemia (WM)

DrugAcalabrutinib

Acerta Pharma BV

Phase 2

107

Bournemouth, Leeds, Leicester, London, Oxford, Plymouth, Southampton

2014-09-11

Active, closed

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

NCT02029443Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia

DrugAcalabrutinib

Acerta Pharma BV

Phase 1/2

306

Leeds, London, Oxford

2014-01-30

Active, closed

Zimmer POLAR Persona - TKA (EMEA Study)

NCT02337244Severe Knee Pain, Severe Knee Disability, Osteoarthritis, Rheumatoid Arthritis

Zimmer, GmbH

Observational

777

Leeds, Clydebank, Harrogate, Newcastle

2013-11-18

Active, closed

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

NCT01946204Prostatic Neoplasms

DrugApalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,207

Blackburn, Cambridge, Cardiff, Dundee, Glasgow, Guildford, Leeds, London

2013-10-14

Active, closed

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

DrugIbrutinib

Janssen Research & Development, LLC

Phase 3

539

Birmingham, Bournemouth, Colchester, Glasgow, Leeds, Leicester, London, Manchester

2013-09-09

Active, closed

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

NCT01843374Unresectable Pleural or Peritoneal Malignant Mesothelioma

DrugTremelimumab

MedImmune LLC

Phase 2

571

Leeds, Leicester, London, Maidstone, Manchester, Metropolitan Borough of Wirral, Plymouth, Southampton

2013-05-17

Recruiting

RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain

NCT01719055Pain

Boston Scientific Corporation

Observational

4,800

Basildon, Bristol, Leeds, London, Middlesbrough, Stanmore

2012-11-19

Active, closed

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

NCT01838512Multiple Myeloma

Bristol-Myers Squibb

Observational

2,555

Truro, Leeds, Liverpool, Nottingham, Stafford, Swansea

2012-06-13

Recruiting

Patient Retrospective Outcomes (PRO)

NCT01550575Chronic Pain

Boston Scientific Corporation

Observational

15,000

Basildon, Bristol, Exeter, Leeds, London, Middlesbrough

2012-04-03

Active, closed

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

NCT01586910Severe Aortic Stenosis

Medtronic Cardiovascular

Not applicable

1,746

Leeds, Leicester, London

2012-04

Recruiting

Product Surveillance Registry

NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders

Medtronic

Observational

100,000

Barnstaple, Birmingham, Blackpool, Bristol, Chelmsford, Glasgow, Harrow, Leeds

2012-01

Recruiting

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

NCT00903110IGF1 Deficiency

Esteve Pharmaceuticals, S.A.

Observational

500

Belfast, Birmingham, Leeds, London, Manchester

2008-12-09

Recruiting

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

NCT00271180Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia

Medtronic

Observational

20,000

Birmingham, Blackpool, Bristol, Leeds, Leicester, Liverpool, London, Manchester

1983-01

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-uk/city/leeds

Query this register directly

GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 10 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 321 of those studies with a site in Leeds.

How many clinical trials are recruiting in Leeds?

150 of the 321 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:15 UTC sync. A further 8 have not yet opened recruitment, 160 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Leeds), 321 studies
Phase	Studies	Recruiting	Share
Phase 3	159	68	49.5%
Phase 2	51	15	15.9%
Observational	28	22	8.7%
Phase 1/2	28	21	8.7%
Not applicable	18	7	5.6%
Phase 1	17	7	5.3%
Phase 4	11	5	3.4%
Phase 2/3	9	5	2.8%

Most active sponsors

Lead sponsors with the most studies (Leeds)
Lead sponsor	Studies	Recruiting
AstraZeneca	28	15
Janssen Research & Development, LLC	13	4
AbbVie	10	3
BeOne Medicines	9	4
Bristol-Myers Squibb	9	4
Hoffmann-La Roche	9	1
Merck Sharp & Dohme LLC	9	5
Novartis Pharmaceuticals	9	3
BioNTech SE	8	5
Eli Lilly and Company	8	8

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.